The latest results of the EAST – AFNET 4 study will be presented at this year’s ESC Congress 2021 (streamed live):
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
Friday, 27th of August 2021 | 10.30am – 11:15am (CEST)
Presented by Prof. Dr. Stephan Willems
Die neuesten Ergebnisse der EAST-AFNET 4 Studie werden auf dem diesjährigen ESC Congress 2021 als Live-Stream präsentiert:
Late Breaking Science in Arrhythmias
Benefit of early rhythm control therapy in patients with asymptomatic AF -insights from EAST-AFNET 4
27.08.2021 | 10:30 – 11:15 Uhr (CEST)
Präsentiert von Prof. Dr. Stephan Willems
A subgroup analysis of the EAST – AFNET 4 study population revealed: Early initiation of rhythm control therapy is associated with clinical benefit in patients with heart failure and recently diagnosed atrial fibrillation. The new findings were presented by Dr. Andreas Rillig, UKE Hamburg, at the HRS congress on 30.07.2021 [1], [2].
The latest results of the EAST – AFNET 4 study will be presented at this year’s HRS in Boston.
Early Rhythm Control Therapy In Patients With Atrial Fibrillation And Heart Failure (PD Dr. Andreas Rillig)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
10:45am – 10:53am Eastern time / 4:45pm – 4:53pm CEST
More information
Early Rhythm Control for the Treatment of Atrial Fibrillation (Prof. Dr. Paulus Kirchhof)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
1:30pm – 2:30pm Eastern time / 7:30pm – 8:30pm CEST
More information
The latest results of the EAST – AFNET 4 study will be presented at this year’s HRS in Boston.
Early Rhythm Control Therapy In Patients With Atrial Fibrillation And Heart Failure (PD Dr. Andreas Rillig)
Live-Stream from the Heart Rhythm Society (HRS 2021), Boston, USA.
Friday, 30 July 2021
10:45am – 10:53am Eastern time / 4:45pm – 4:53pm CEST
The desing paper of the AFFECT-EU project “Digital, risk-based screening for atrial fibrillation in the EU” has recently been published in the European Heart Journal.
The paper can be accessed here.
Our publication of the EAST-AFNET 4 results in the New England Journal of Medicine “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation“ was read over 90.000 (and cited 48) times across all 5 continents. Two “Letters to the Editor” including the answers of the authors were recently released. Please read.
The Smart in OAC – AFNET 9 study is testing whether unknown atrial fibrillation (AF) can be detected via an app and a monitoring bracelet. It is the objective to detect AF at an early stage using modern technologies. The number of newly detected, previously unknown episodes of atrial fibrillation and the effectivity of the program will be evaluated.
Especially in elderly patients, an infection with Covid-19 often takes a severe course. Therefore, AFNET recommends these patients to get vaccinatied as soon as possible. The protection by the vaccination outweighs possible vaccination risks by far.
Patients with newly diagnosed atrial fibrillation (AF) benefit from early rhythm control therapy, according to results of EAST – AFNET 4, an AFNET/EHRA trial presented in a Hot Line session today at ESC Congress 2020[1,2]. Early rhythm control therapy with antiarrhythmic drugs and/or AF ablation reduced a composite of cardiovascular death, stroke, and hospitalization for worsening heart failure or acute coronary syndrome in 2789 patients with early AF and cardiovascular risk factors compared to usual care over a 5-year follow-up time.
